Evidence map›Paper›PMID 36542775›Full record

ArticleOcular immunology and inflammation2024

Efficacy and Safety of Tocilizumab in the Management of Non-Infectious Uveitis Failed with Conventional Immunomodulatory and Anti-TNFα Therapies.

Gunay Uludag, Irmak Karaca, Amir Akhavanrezayat, Cigdem Yasar, Wataru Matsumiya, Brandon Huy Pham, Muhammad Sohail Halim, Ngoc Trong Tuong Than, Yasir J Sepah, Diana V Do and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular immunology and inflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Tocilizumab for Non-Infectious Uveitis: A Systematic Review.Journal of inflammation research · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Gunay UludagDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Irmak KaracaDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.ORCID 0000-0001-7927-0887
Amir AkhavanrezayatDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Cigdem YasarDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Wataru MatsumiyaDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Brandon Huy PhamDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.ORCID 0000-0002-4482-332X
Muhammad Sohail HalimDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Ngoc Trong Tuong ThanDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Yasir J SepahDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Diana V DoDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Quan Dong NguyenDepartment of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Smith-Kettlewell Eye Research Institute · USOcular Surface Center · USUniversity of Miami Health System · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

purposeTo determine the outcomes of intravenous (IV) tocilizumab (TCZ) in patients with non-infectious uveitis who failed with conventional immunomodulatory and anti-TNFα therapies.

methodsRecords of seven patients with non-infectious uveitis treated with monthly IV TCZ (4-10 mg/kg) or biweekly IV TCZ (8 mg/kg) were reviewed. Outcome measures were changes in visual acuity, anterior chamber cell and flare grade, vitreous haze, central subfield thickness (CST), and fluorescein angiography (FA) score.

resultsTen eyes of seven patients received TCZ therapy. Median age of patients was 14 (range, 7-24) years. Median duration of TCZ therapy was 15 (range, 5-32) months. Mean CST reduced from 373 ± 101.0 μm to 298.2 ± 40.3 μm. Mean FA score reduced from 12.5 ± 4.3 to 3.6 ± 2.6. One patient developed elevated liver transaminases.

conclusionIV TCZ is a potentially effective and safe therapeutic option for the management of refractory non-infectious uveitis.

Indexed as

Antibodies, Monoclonal, HumanizedFluorescein AngiographyTumor Necrosis Factor-alphaUveitisVisual AcuityAdolescentChildFemaleHumansMaleRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeYoung AdultAntibodies, Monoclonal, HumanizedtocilizumabTumor Necrosis Factor-alphaCentral subfield thicknessfluorescein angiography scorenon-infectious uveitisretinal vasculitistocilizumab

Identifiers

PMID36542775
PMCPMC10863989
OpenAlexW4312095050

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.